Publication Database

Mesenchymal stem cells and their extracellular vesicles as a future treatment strategy for equine and human asthma?
a literature review (2025)

Art

Vortrag

Autoren

Stage, Hannah J. (WE 17)

Gehlen, Heidrun (WE 17)

Kongress

2nd International Conference on Cell Science and Regenerative Medicine

Barcelona, Spain, 08. – 09.09.2025

Quelle

2nd International Conference on Cell Science and Regenerative Medicine : Conference Proceedings — United Research Forum (Hrsg.)

— S. 20–21

Sprache

Englisch

Verweise

URL (Volltext): https://assets.unitedresearchforum.com/proceedings/hannah-julia-stage_3342_295.pdf

DOI: 10.51219/URForum.2025.Hannah-Julia-Stage

Kontakt

Pferdeklinik

Oertzenweg 19 b
14163 Berlin
+49 30 838 62299 / 62300
pferdeklinik@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Abstract: Asthma is a chronic, inflammatory, non-infectious respiratory disease with high prevalence in humans and horses. Severe equine asthma (EA) exerts strong similarities to human asthma (HA). In both species, treatment success is not always successful and includes bronchodilators, mucolytics and corticosteroids, whereas the latter can cause systemic side effects, underlying the need for new treatment strategies. Multipotent mesenchymal stem cells (MSCs) mainly act through their extracellular vesicles (MSC-EVs) with promising antiinflammatory and immunomodulatory paracrine effects and could therefore be used as new treatment option for lung diseases. The study´s aim was to compare the therapeutic effects of MSCs and MSC-EVs in EA and HA based on the `One Medicine, one Health´ approach.
The research question addressed whether asthmatic human patients could benefit from new treatment approaches of asthma affected horses and vice versa. An extensive literature search was carried out, including publications between 2010 and 2025. In EA and HA first clinical studies investigated the safety and clinical efficiency of MSCs, whereas, to the best of the author´s knowledge, MSC-EVs have not yet been used in these patients clinically. In horses with severe EA a first study showed that intrabronchial applicated autologous adipose tissue-derived MSCs significantly improved long-term clinical symptoms after one year. In 2022, the first human asthmatic patient benefited significantly from intravenously applied allogenic umbilical cord-derived MSCs two and six months after treatment, as demonstrated by reduction in nebulizer usage. Further single clinical studies followed. In conclusion, the horse represents a suitable model for allergic neutrophilic HA.
Further studies investigating the clinical efficiency of MSCs and especially their MSC-EVs will lead to better treatment options for both, humans and horses.